Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
biliary cirrhosis
Pharma
Ipsen pays $952M to acquire Albireo and liver disease med Bylvay
Ipsen is set to acquire rare disease specialist Albireo for $952 million. The AZ spinout is developing drugs to treat pediatric liver diseases.
Kevin Dunleavy
Jan 9, 2023 10:05am
Albireo's Bylvay aces test in a 2nd pediatric liver disease
Oct 11, 2022 8:25am
AstraZeneca's blockbuster Imfinzi flunks cervical cancer trial
Mar 24, 2022 9:26am
With Bylvay launch, transformed Alberio enters a new era
Mar 22, 2022 2:46pm
